Effect of intravenous dopamine infusion on pituitary and thyroid function and on nephroprotection

Polskie Archiwum Medycyny Wewnetrznej

Volumn 122, Issue 3, 2012, Pages 82-88

  Kobusiak Prokopowicz, Małgorzata ^a   Ściborski, Krzysztof ^a   Mysiak, Andrzej ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Adrenocorticotropic hormone; Dopamine; Heart failure; Nephroprotection; Thyroid stimulating hormone

Indexed keywords

CORTICOTROPIN; DOPAMINE; LIOTHYRONINE; THYROTROPIN; THYROXINE;

ACUTE HEART FAILURE; AGED; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CORTICOTROPIN BLOOD LEVEL; CREATININE CLEARANCE; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; HUMAN; HYPOPHYSIS FUNCTION; LIOTHYRONINE BLOOD LEVEL; MALE; RENAL PROTECTION; STATISTICAL SIGNIFICANCE; THYROID FUNCTION; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

EID: 84859486179     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1200     Document Type: Article

References (26)

1. Missale C, Nash SR, Robinson SW, et al. Dopamine receptors: from structure to function. Physiol Rev. 1998; 78: 189-225. (Pubitemid 28070979)
2. Elsworth JD, Roth RH. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson''s disease. Exp Neurol. 1997; 144: 4-9. (Pubitemid 27149594)
3. Drożak J, Bryła J. Dopamine: not just a neurotransmitter. Postepy Hig Med Dosw. 2005; 59: 409-412.
4. Eisler T, Thorner MO, MacLeod RM, et al. Prolactin secretion in Parkinson disease. Neurology. 1981; 31: 1356-1359. (Pubitemid 11026863)
5. Trzebski A. [Blood flow through various vascular regions and regulation of blood pressure. In: Human physiology with components of clinical and applied physiology]. Traczyk Z, Trzebski A, eds. Warszawa, Poland: Wydawnictwo Lekarskie PZWL; 2001: 589-628. Polish.
6. Järnberg PO, Bengtsson L, Ekstrand J, Hamberger B. Dopamine infusion in man. Plasma catecholamine levels and pharmacokinetics. Acta Anaesthesiol Scand. 1981; 25: 328-331. (Pubitemid 11017663)
7. Lieverse AG, Lefrandt JD, Girbes AR, et al. The effects of different doses of dopamine and domperidone on increases of plasma norepinephrine induced by cold pressor test in normal man. Hypertens Res. 1995; Suppl 1: S221-224.
8. Jose PA, Eisner GM, Felder RA. Renal dopamine and sodium homeostasis. Curr Hypertens Rep. 2000; 2: 174-183.
9. Girbes AR, Patten MT, McCloskey BV, et al. The renal and neurohumoral effects of the addition of low-dose dopamine in septic critically ill patients. Intensive Care Med. 2000; 26: 1685-1689.
10. Lumlertgul D, Keoplung M, Sitprija V, et al. Furosemide and dopamine in malarial acute renal failure. Nephron. 1989; 52: 40-44. (Pubitemid 19098520)
11. Dive A, Foret F, Jamart J, et al. Effect of dopamine on gastrointestinal motility during critical illness. Intensive Care Med. 2000; 26: 901-907. (Pubitemid 30616043)
12. Olson D, Pohlman A, Hall JB. Administration of low-dose dopamine to nonoliguric patients with sepsis syndrome does not raise intramucosal gastric pH nor improve creatinine clearance. Am J Respir Crit Care Med. 1996; 154: 1664-1670. (Pubitemid 26424932)
13. Bellomo R, Chapman M, Finfer S, et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet. 2000; 356: 2139-2143. (Pubitemid 32047951)
14. Marik PE, Iglesias J. Low-dose dopamine does not prevent acute renal failure in patients with septic shock and oliguria. NORASEPT II Study Investigators. Am J Med. 1999; 107: 387-390.
15. Van den Berghe G, de Zegher F, Vlasselaers D, et al. Thyrotropin- releasing hormone in critical illness: from a dopamine-dependent test to a strategy for increasing low serum triiodothyronine, prolactin, and growth hormone concentrations. Crit Care Med. 1996; 24: 590-595.
16. Van den Berghe G, de Zegher F, Veldhuis JD, et al. Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues. Clin Endocrinol (Oxf). 1997; 47: 599-612. (Pubitemid 27496335)
17. De Zegher F, Van Den Berghe G, Devlieger H, et al. Dopamine inhibits growth hormone and prolactin secretion in the human newborn. Pediatr Res. 1993; 34: 642-645. (Pubitemid 23312796)
18. Mikawa K, Kusunoki M, Obara H, Iwai S. Effect of dopamine on plasma growth hormone and prolactin concentrations under anaesthesia. J Int Med Res. 1988; 16: 403-412. (Pubitemid 19005183)
19. Filippi L, Pezzati M, Cecchi A, et al. Dopamine infusion and anterior pituitary gland function in very low birth weight infants. Biol Neonate. 2006; 89: 274-280. (Pubitemid 43886942)
20. Van den Berghe G, de Zegher F, Lauwers P. Dopamine and the sick euthyroid syndrome in critical illness. Clin Endocrinol (Oxf). 1994; 41: 731-737.
21. Ciobanu L, Dumitrascu DL. Gastrointestinal motility disorders in endocrine diseases. Pol Arch Med Wewn. 2011; 121: 129-136.
22. Aron DC. Hormone screening in the patients with incidentally discovered pituitary mass: Current practice and factors in clinical decision making. Endocrinologist. 1995; 5: 357-359.
23. Fassbender K, Schmidt R, Mössner R, et al. Pattern of activation of the hypothalamic-pituitary-adrenal axis in acute stroke. Relation to acute confusional state, extent of brain damage, and clinical outcome. Stroke. 1994; 25: 1105-1108.
24. Kellum JA, M Decker J, Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med. 2001; 29: 1526-1531. (Pubitemid 32762331)
25. Mebazaa A. Current ESC/ESICM and ACCF/AHA guidelines for the diagnosis and management of acute heart failure in adults - are there differences? Pol Arch Med Wewn. 2009; 119: 569-572.
26. Debaveye YA, Van den Berghe GH. Is there still a place for dopamine in the modern intensive care unit? Anesth Analg. 2004; 98: 461-468. (Pubitemid 38129397)